BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2138351)

  • 1. [Current aspects and trends in immunotherapy of cancer].
    Boniver J; Schaaf-Lafontaine N; Moutschen M; Longrée L; Lovens-Degraef D; Fassotte MF; Reginster MA; Simonet-Martin MT; Baudrihaye M
    Rev Med Liege; 1990 Feb; 45(2):41-8. PubMed ID: 2138351
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphokine-activated killer cells/tumor-infiltrating lymphocytes therapy: efficacy, toxicity, controversies.
    Dutcher JP
    J Clin Apher; 1990; 5(2):80-2. PubMed ID: 2404970
    [No Abstract]   [Full Text] [Related]  

  • 3. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 5. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells.
    Lewalle P; Hensel N; Guimaraes A; Couriel D; Jiang Y Z; Mavroudis D; Barrett AJ
    Br J Haematol; 1996 Mar; 92(3):587-94. PubMed ID: 8616022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
    Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
    Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant antibody fusion proteins for cancer immunotherapy.
    Reisfeld RA; Gillies SD
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
    [No Abstract]   [Full Text] [Related]  

  • 8. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
    G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
    Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
    Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.
    Lotzová E
    Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction and expansion of LAK cells for cancer immunotherapy.
    Hamblin TJ
    Prog Clin Biol Res; 1990; 337():551-3. PubMed ID: 2353017
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunotherapy for malignant glioblastoma].
    Nose T; Nakagawa K
    No Shinkei Geka; 1995 Mar; 23(3):195-206. PubMed ID: 7700486
    [No Abstract]   [Full Text] [Related]  

  • 14. Adoptive immunotherapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1994; 15():213-25. PubMed ID: 7779587
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of T lymphocytes in the immunotherapy of tumours.
    Brondz BD; Balashov KE
    Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine activated killer cells: a new approach to immunotherapy of cancer.
    Semenzato G
    Leukemia; 1990 Feb; 4(2):71-80. PubMed ID: 2406518
    [No Abstract]   [Full Text] [Related]  

  • 17. Approaches to immunotherapy of cancer: characterization of lymphokines as second signals for cytotoxic T-cell generation.
    Bertagnolli MM; Herrmann SH; Pinto VM; Schoof DD; Eberlein TJ
    Surgery; 1991 Sep; 110(3):459-68. PubMed ID: 1887370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
    Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
    Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1992; 13():191-204. PubMed ID: 1389910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.